Scientific context only. Not medical advice, not a recommendation to use.
At a glance
Maridebart cafraglutide (MariTide, Amgen) is a bispecific molecule: a GLP-1receptoragonist combined with a GIP receptor antagonist, designed for monthly dosing; in phase 3 for obesity.
Researched for
ObesityType 2 diabetesWeight management
Official status
US: Unapproved
Investigational; phase-3 programme ongoing, not approved.
MariTide combines GLP-1receptor agonism with GIP receptor antagonism in an antibody-peptide conjugate. Its long duration of action allows infrequent (monthly) dosing.
02
Evidence at a glance
Reading note. The distribution shows on which evidence tier each observation sits. Strong colours mark stronger evidence — weaker tiers are deliberately visible, not hidden.
2 observations · single evidence tier
Human RCT
2
03
What the studies show
Human RCT
Mensch
Maridebart Cafraglutide (MariTide) for O 2025
In the phase-2 study, participants without diabetes achieved a mean weight loss of up to about 20% at 52 weeks — with no apparent plateau.
What does NOT follow: Phase 2; the phase-3 programme is ongoing, not yet approved.
Human RCT
Mensch
Maridebart Cafraglutide (MariTide) for O 2025
In participants with type 2 diabetes the mean weight loss was about 17%, and HbA1c fell by up to 2.2 percentage points.
What does NOT follow: Investigational; a factual report of the reported results.
05
Pharmacokinetics
No robust pharmacokinetic human data available. A model curve is not invented.
06d
Safer use & risks
Risk notes for harm reduction — descriptive, not a usage or dosing guide.
⚠ Important — please read
This platform does NOT provide usage or dosing instructions. The points below describe risks and are meant to help avoid harm — they do not replace medical advice. Anyone who uses a substance should discuss it with a doctor.
There is no approved human use for this substance. What circulates online about amounts and frequency is self-experimentation without a safety net.
Online numbers are not a benchmark
Amounts from TikTok, YouTube and forums are mostly imitation rather than data — and are often wrongly derived from animal studies (µg/kg). Not a reliable benchmark for humans.
Sterility & infection risk
Injection solutions prepared or stored non-sterile carry an infection and abscess risk. Contamination is common with grey-market product.
Unknown product quality
Research-/grey-market product is not quality-tested: identity, purity and actual content are often unknown, and counterfeits occur.
Mind interactions
Combinations with medications or pre-existing conditions can carry risks (see the Interactions section). Clarify with a doctor beforehand.
Warning signs — seek medical help
With persistent pain, redness/swelling at the injection site, fever, shortness of breath, racing heart, chest pain or allergic reactions, seek medical help immediately.
A doctor, not a forum
Concrete questions about use and amount belong in a conversation with a doctor — not in a comment thread.
07
Known adverse events from studies
Factual reporting of what studies observed. Not a safety statement for individual use.
Human trial
Gastrointestinal effects (nausea, vomiting) — class-typical, related to dose escalation
Reported as predominantly mild to moderate; a factual report.
häufig
07b
Interactions & combinations
Documented interactions and contraindications from studies, prescribing information and guidelines. Where no data exists, this is stated.
Reporting of risks, NOT a combination guide. The absence of an entry does not mean „safe to combine“ but „not sufficiently studied“.
No documented interactions recorded
We have not yet found robustly documented interactions for this peptide. This does NOT mean none exist — the data is limited.
11
Legal status by country
Country
Status
Note
Checked
United States
Unapproved
Investigational; phase-3 programme ongoing, not approved.
2026-06
Germany
Unapproved
Not approved; no EU market access.
2026-06
12
Reconstitution calculator
Pure mg/mL maths — works like a calculator. Not a usage recommendation.
Peptides ship as a dry powder. Once dissolved in a liquid (reconstitution), this calculator answers a single question: how much substance is in one millilitre of solution afterwards?
1Enter the vial's substance amount (printed on the label).
2Enter how much solvent you add.
3Result = concentration in mg per mL.
Printed on the label
/
Liquid you add
=
2.50
mg / mL
5 mg in 2 mL gives 2.50 mg/mL — each millilitre contains 2.50 mg of substance.